TAS 102

Aliases

Lonsurf

7 clinical trials

1 abstract

8 indications

Indication

Pancreatic Cancer

Indication

Indication

Stomach Adenocarcinoma

Indication

Esophageal Cancer

Indication

Pancreatic Ductal Adenocarcinoma

Indication

Indication

Colorectal Cancer

Indication

Metastatic Adenocarcinoma of the Gastroesophageal Junction

Abstract

Predictors of survival outcome of TAS102 combined with bevacizumab compared to TAS102 alone in Saudi patients with metastatic colorectal cancer beyond second line of systemic therapy.

Org: Makkah Saudi Arabia, King Abdulla Medical City/Makkah, Mekkah, Umm AlQura University, King Abdulaziz Medical City (NGHA),

Clinical trial

Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2024-03-25

Clinical trial

TAS-102 Combined With Anlotinib in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments (THALIA): a Prospective Single-arm Phase II Study

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-01-19

Clinical trial

Phase I Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Status: Terminated, Estimated PCD: 2021-05-10

Clinical trial

SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial

Status: Completed, Estimated PCD: 2023-12-14

Clinical trial

A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based Therapy

Status: Completed, Estimated PCD: 2022-01-13